CYPH — Cypherpunk Technologies Inc.
NASDAQ · Financial Services · Asset Management
$1.62
-$0.09 (-5.20%)
Cypherpunk Technologies Inc. (CYPH) is a asset management company listed on NASDAQ. It is led by Douglas E. Onsi J.D., based in 47 Thorndike Street, Cambridge, MA, United States, 02141, with about 6 employees. Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash. It also develops biomarker-targeted antibody therapies for patients with cancer and other diseases comprising DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which has completed Phase 2 study for the treatment of colorectal cancer; and FL-501, a monoclonal antibody inhibiting the GDF-15 protein, which is in preclinical development to treat cancer cachexia, hyperemesis gravidarum and pregnancy-related nausea and vomiting, and other diseases associated with aging and frailty. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. Cypherpunk Technologies Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Net income was -$35.4M. CYPH currently screens at market cap $79.3M.
Use this CYPH page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CYPH quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CYPH SEC filings page. Lician reads the product cache first so this HTML stays unique to Cypherpunk Technologies Inc. even when a live quote feed is slow.
About Cypherpunk Technologies Inc.
Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash. It also develops biomarker-targeted antibody therapies for patients with cancer and other diseases comprising DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which has completed Phase 2 study for the treatment of colorectal cancer; and FL-501, a monoclonal antibody inhibiting the GDF-15 protein, which is in preclinical development to treat cancer cachexia, hyperemesis gravidarum and pregnancy-related nausea and vomiting, and other diseases associated with aging and frailty. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. Cypherpunk Technologies Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
CYPH Key Statistics
Market Cap
$79.26M
Volume
37.70M
Previous Close
$1.42
Day Range
$1.53 – $2.02
P/B Ratio
1.03
EPS
-$1.81
Revenue
$0.00
Net Income
-$67.56M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
6
CYPH Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $1.50M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$67.56M | -$81.41M | -$54.60M | -$40.59M |
| EPS (Diluted) | -$1.81 | -$3.98 | -$4.82 | -$0.47 |
Total Assets
$49.12M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$47.25M
Operating Cash Flow
-$60.30M
Free Cash Flow
$0.00
Cypherpunk Technologies Inc. Company Information
- CFO, General Counsel, Treasurer & Secretary, President, CEO & Director
- Douglas E. Onsi J.D.
- Headquarters
- 47 Thorndike Street, Cambridge, MA, United States, 02141
- Website
- www.cypherpunk.com
- Phone
- 617 714 0360
- IPO / Founded
- 2017-01-25
- Sector
- Financial Services
- Industry
- Asset Management